ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

BTVPUR AlSap 2-4 suspension for injection for sheep

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each dose of 1ml of vaccine contains:

Active substances:
Bluetongue virus serotype 2 antigen ..... 6.8–9.5 $CCID_{50}$*
Bluetongue virus serotype 4 antigen ..... 7.1–8.5 $CCID_{50}$*
* Cell culture infectious dose 50% equivalent to titre prior to inactivation (log_{10})

Adjuvants:

Aluminium hydroxide	2.7 mg,
Saponin	30 HU**

**Haemolytic units

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Suspension for injection.

4. CLINICAL PARTICULARS

4.1 Target species

Sheep

4.2 Indications for use, specifying the target species

Active immunisation of sheep to prevent viraemia* and to reduce clinical signs caused by bluetongue virus serotypes 2 and 4.
*(below the level of detection by the validated RT-PCR method at 3.68 log_{10} RNA copies/ml, indicating no infectious virus transmission)

Onset of immunity has been demonstrated 3 and 5 weeks after the primary vaccination course for serotype 4 and serotype 2, respectively.

The duration of immunity is 1 year after primary vaccination course.

4.3 Contraindications

None.

4.4 Special warnings for each target species

If used in other domestic and wild ruminant species that are considered at risk of infection, its use in these species should be undertaken with care and it is advisable to test the vaccine on a small number of animals prior to mass vaccination. The level of efficacy for other species may differ from that observed in sheep.

4.5 Special precautions for use

Special precautions for use in animals

Vaccinate healthy animals only.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Not applicable.

4.6 Adverse reactions (frequency and seriousness)

Vaccination may be followed by a small local swelling at the injection site (at most 24 cm^2) for a short period (at most 14 days).
A transient increase in body temperature, normally not exceeding an average of 1.1 °C, may occur within 24 hours after vaccination.

4.7 Use during pregnancy, lactation or lay

Can be used during pregnancy and lactation.
The safety and the efficacy of the vaccine have not been established in breeding males. In this category of animals the vaccine should be used only according to the benefit-risk assessment by the responsible veterinarian and/or National Competent Authorities on the current vaccination policies against bluetongue virus (BTV).

4.8 Interaction with other medicinal products and other forms of interaction

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be decided on a case by case basis.

4.9 Amounts to be administered and administration route

Subcutaneous use.

Apply usual aseptic procedures.
Shake gently immediately before use. Avoid bubble formation, as this can be irritating at the site of injection. The entire content of the bottle should be used immediately after broaching and during the same procedure. Avoid multiple vial broaching.

Administer one dose of 1 ml subcutaneously according to the following vaccination scheme:

Primary vaccination
One injection: from 1 month of age in naive animals (or from 2.5 months of age in young animals born to immune sheep).

Revaccination
Annual.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

No adverse reactions except those mentioned in section 4.6 were observed after the administration of a double-dose of the vaccine.

4.11 Withdrawal period

Zero days.

5. IMMUNOLOGICAL PROPERTIES

Pharmacotherapeutic group: inactivated bluetongue virus vaccine for sheep.
ATCvet code QI04AA02.

The vaccine contains inactivated bluetongue virus serotypes 2 and 4 with aluminium hydroxide and saponin adjuvants. It induces an active and specific immunity against bluetongue virus serotypes 2 and 4 in the vaccinated animals.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Silicon antifoam
Phosphate buffer
Glycine buffer
Aluminium hydroxide
Saponin.

6.2 Incompatibilities

Do not mix with any other veterinary medicinal products.

6.3 Shelf life

Shelf life of the veterinary medicinal product as package for sale: 18 months.
Shelf life after first opening the immediate packaging: use immediately.

6.4 Special precautions for storage

Store and transport refrigerated (2 °C – 8 °C).
Do not freeze.
Protect from light.

6.5 Nature and composition of immediate packaging

Polypropylene bottle of 50 or 100 ml with butyl elastomer closure.

Box of 1 bottle of 100 doses (1 x 100 ml).
Box of 10 bottles of 100 doses (10 x 100 ml).
Box of 1 bottle of 50 doses (1 x 50 ml).
Box of 10 bottles of 50 doses (10 x 50 ml).

Type I glass bottle of 10 ml with butyl elastomer closure.
Box of 1 bottle of 10 doses (1 x 10 ml).

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

MERIAL
29, avenue Tony Garnier
69007 Lyon
FRANCE

8. MARKETING AUTHORISATION NUMBER(S)

EU/2/10/108/001
EU/2/10/108/002
EU/2/10/108/003
EU/2/10/108/004
EU/2/10/108/005

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

05/11/2010

10. DATE OF REVISION OF THE TEXT

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).

PROHIBITION OF SALE, SUPPLY AND/OR USE

The manufacture, import, possession, sale, supply and/or use of BTVPUR AlSap 2-4 may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation. Any person intending to manufacture, import, possess, sell, supply and use BTVPUR AlSap 2-4 must consult the relevant Member State's competent authority on the current vaccination policies prior to the manufacture, import, possession, sale, supply and/or use.

ANNEX II

A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. STATEMENT OF THE MRLs

D. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturers of the biological active substances

MERIAL Animal Health Limited
Biological Laboratory, Ash Road,
Pirbright, Woking, Surrey GU24 0NQ
UNITED KINGDOM

MERIAL Laboratoire de Lyon Gerland
254, rue Marcel Mérieux
69342 LYON CEDEX 07
FRANCE

Name and address of the manufacturer responsible for batch release

MERIAL
Laboratory of Lyon Porte des Alpes
Rue de l'Aviation,
69800 Saint-Priest
FRANCE

B. CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION REGARDING SUPPLY OR USE

Veterinary medicinal product subject to prescription.

According to Article 71 of Directive 2001/82/EC of the European Parliament and of the Council as amended, a Member States may, in accordance with its national legislation, prohibit the manufacture, import, possession, sale, supply and/or use of immunological veterinary medicinal products on the whole or part of their territory if it is established that:

a) the administration of the product to animals will interfere with the implementation of national programmes for the diagnosis, control and eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.

b) the disease to which the product is intended to confer immunity is largely absent from the territory in question.

The use of this veterinary medicinal product is only allowed under the particular conditions established by European Community legislation on the control of bluetongue.

C. STATEMENT OF THE MRLs

The active substance being a principle of biological origin intended to produce active immunity is not in the scope of Regulation (EC) 470/2009.
The excipients (including adjuvants) listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.

D. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

1. The marketing authorization holder should provide a suitable system for quantifying active ingredient at blending stage as soon as feasible.

2. The periodic safety update report (PSUR) cycle should be re-started for submission of 6 monthly reports (covering all authorised presentations of this product) for the next two years, followed by yearly reports for the subsequent two years and thereafter at three-yearly intervals.

ANNEX III

LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Box of 1 bottle of 10 ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

BTVPUR AlSap 2-4 suspension for injection for sheep

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

Each dose of 1ml of vaccine contains:
BTV2 antigen .....6.8–9.5 $CCID_{50}$*,
BTV4 antigen .....7.1–8.5 $CCID_{50}$*,
Aluminium hydroxide, Saponin, qs 1 dose *.
*see package leaflet.

3. PHARMACEUTICAL FORM

Suspension for injection

4. PACKAGE SIZE

10 doses (10 ml)

5. TARGET SPECIES

Sheep

6. INDICATION(S)

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Subcutaneous use.
Read the package leaflet before use.

8. WITHDRAWAL PERIOD

Withdrawal period: zero days.

9. SPECIAL WARNING(S), IF NECESSARY

Read the package leaflet before use.

10. EXPIRY DATE

EXP {month/year}
Once broached, use immediately.

11. SPECIAL STORAGE CONDITIONS

Store and transport refrigerated (2 °C – 8 °C).
Do not freeze.
Protect from light.

12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Read the package leaflet before use.

13. THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable

For animal treatment only. To be supplied only on veterinary prescription.

14. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

MERIAL
29, avenue Tony Garnier
69007 Lyon
FRANCE

16. MARKETING AUTHORISATION NUMBER(S)

EU/2/10/108/005

17. MANUFACTURER'S BATCH NUMBER

Lot {number}

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Box of 1 bottle of 50 ml, or of 10 bottles of 50 ml, or of 1 bottle of 100 ml, or of 10 bottles of 100 ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

BTVPUR AlSap 2-4 suspension for injection for sheep

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

Each dose of 1ml of vaccine contains:
BTV2 antigen .....6.8–9.5 $CCID_{50}$*
BTV4 antigen .....7.1–8.5 $CCID_{50}$*
Aluminium hydroxide, Saponin, qs 1 dose*.
*see package leaflet.

3. PHARMACEUTICAL FORM

Suspension for injection

4. PACKAGE SIZE

50 doses (50 ml)
10 bottles of 50 doses (10 x 50 ml)
100 doses (100 ml)
10 bottles of 100 doses (10 x 100 ml)

5. TARGET SPECIES

Sheep

6. INDICATION(S)

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Subcutaneous use.
Read the package leaflet before use.

8. WITHDRAWAL PERIOD

Withdrawal period: zero days.

9. SPECIAL WARNING(S), IF NECESSARY

Read the package leaflet before use.

10. EXPIRY DATE

EXP {month/year}
Once broached, use immediately.

11. SPECIAL STORAGE CONDITIONS

Store and transport refrigerated (2 °C – 8 °C).
Do not freeze.
Protect from light.

12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Read the package leaflet before use.

13. THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable

For animal treatment only. To be supplied only on veterinary prescription.

14. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

MERIAL
29, avenue Tony Garnier
69007 Lyon
FRANCE

16. MARKETING AUTHORISATION NUMBER(S)

EU/2/10/108/003 (1 bottle of 50 ml)
EU/2/10/108/004 (10 bottles of 50 ml)
EU/2/10/108/001 (1 bottle of 100 ml)
EU/2/10/108/002 (10 bottles of 100 ml)

17. MANUFACTURER'S BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

Bottle of 10 or 50 ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

BTVPUR AlSap 2-4 suspension for injection for sheep

2. QUANTITY OF THE ACTIVE SUBSTANCE(S)

BTV 2 antigen ..... 6.8–9.5 $CCID_{50}$/ml,
BTV 4 antigen ..... 7.1–8.5 $CCID_{50}$/ml.

3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

10 doses (10 ml)
50 doses (50 ml)

4. ROUTE(S) OF ADMINISTRATION

SC

5. WITHDRAWAL PERIOD

Withdrawal period: zero days.

6. BATCH NUMBER

Lot{number}

7. EXPIRY DATE

EXP {month/year}
Once broached, use immediately.

8. THE WORDS "FOR ANIMAL TREATMENT ONLY"

For animal treatment only.

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE

Bottle of 100 ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

BTVPUR AlSap 2-4 suspension for injection for sheep

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

Each dose of 1ml of vaccine contains:
BTV 2 antigen .....6.8–9.5 $CCID_{50}$,
BTV 4 antigen .....7.1–8.5 $CCID_{50}$

3. PHARMACEUTICAL FORM

Suspension for injection

4. PACKAGE SIZE

100 doses (100 ml)

5. TARGET SPECIES

Sheep

6. INDICATION(S)

7. METHOD AND ROUTE(S) OF ADMINISTRATION

SC.
Read the package leaflet before use.

8. WITHDRAWAL PERIOD

Withdrawal period: zero days.

9. SPECIAL WARNING(S), IF NECESSARY

Read the package leaflet before use.

10. EXPIRY DATE

EXP {month/year}
Once broached, use immediately.

11. SPECIAL STORAGE CONDITIONS

Store and transport refrigerated (2 °C – 8 °C).
Do not freeze.
Protect from light.

12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Read package leaflet before use.

13. THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable

For animal treatment only. To be supplied only on veterinary prescription.

14. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

MERIAL
29, avenue Tony Garnier
69007 Lyon
FRANCE

16. MARKETING AUTHORISATION NUMBER(S)

EU/2/10/108/001 (1 bottle of 100 ml)
EU/2/10/108/002 (10 bottles of 100 ml)

17. MANUFACTURER'S BATCH NUMBER

Lot {number}

B. PACKAGE LEAFLET

PACKAGE LEAFLET FOR:
BTVPUR AlSap 2-4 suspension for injection for sheep

1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder:
MERIAL
29 avenue Tony Garnier
69007 Lyon,
FRANCE

Manufacturer responsible for batch release:
MERIAL
Laboratory of Lyon Porte des Alpes
Rue de l'Aviation,
69800 Saint-Priest
FRANCE

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

BTVPUR AlSap 2-4 suspension for injection for sheep

3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

Each dose of 1 ml of vaccine contains:
Bluetongue virus serotype 2 antigen .....6.8–9.5 $CCID_{50}$*,
Bluetongue virus serotype 4 antigen .....7.1–8.5 $CCID_{50}$*,
Aluminium hydroxide 2.7 mg,
Saponin 30 HU**.
*Cell culture infectious dose 50% equivalent to titre prior to inactivation (log_{10}).
**Haemolytic units.

4. INDICATION(S)

Active immunisation of sheep to prevent viraemia* and to reduce clinical signs caused by bluetongue virus serotypes 2 and 4.
*below the level of detection by the validated RT-PCR method at 3.68 log_{10} RNA copies/ml, indicating no infectious virus transmission.

Onset of immunity has been demonstrated 3 and 5 weeks after the primary vaccination course for serotype 4 and serotype 2, respectively.

The duration of immunity is 1 year after primary vaccination course.

5. CONTRAINDICATIONS

None.

6. ADVERSE REACTIONS

Vaccination may be followed by a small local swelling at the injection site (at most 24 cm²) for a short period (at most 14 days).
A transient increase in body temperature, normally not exceeding an average of 1.1 °C, may occur within 24 hours after vaccination.

If you notice any serious effects or other effects not mentioned in this package leaflet, please inform your veterinary surgeon.

7. TARGET SPECIES

Sheep

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

Administer one dose of 1 ml subcutaneously according to the following vaccination scheme:

Primary vaccination
One injection: from 1 month of age in naive animals (or from 2.5 months of age in young animals born to immune sheep).

Revaccination
Annual.

9. ADVICE ON CORRECT ADMINISTRATION

Apply usual aseptic procedures.
Shake gently immediately before use. Avoid bubble formation, as this can be irritating at the site of injection. The entire content of the bottle should be used immediately after broaching and during the same procedure. Avoid multiple vial broaching.

10. WITHDRAWAL PERIOD

Zero days.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

Store and transport refrigerated (2 °C – 8 °C).
Do not freeze.
Protect from light.

Shelf life after first opening the immediate packaging: use immediately.
Do not use this veterinary medicinal product after the expiry date which is stated on the carton and the label after EXP.

12. SPECIAL WARNINGS

Special warnings for each target species:
If used in other domestic and wild ruminant species that are considered at risk of infection, its use in these species should be undertaken with care and it is advisable to test the vaccine on a small number of animals prior to mass vaccination. The level of efficacy for other species may differ from that observed in sheep.

Special precautions for use in animals:
Vaccinate healthy animals only.

Pregnancy and lactation:
Can be used during pregnancy and lactation.

Fertility:
The safety and the efficacy of the vaccine have not been established in breeding males. In this category of animals the vaccine should be used only according to the benefit-risk assessment by the responsible veterinarian and/or National Competent Authorities on the current vaccination policies against bluetongue virus (BTV).

Interaction with other medicinal products and other forms of interaction:
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be decided on a case by case basis.

Overdose (symptoms, emergency procedures, antidotes):
No adverse reactions except those mentioned in section 'Adverse Reactions' were observed after the administration of a double-dose of vaccine.

Incompatibilities:
Do not mix with any other veterinary medicinal product.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Medicines should not be disposed of via wastewater or household waste.
Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

Detailed information on this product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).

15. OTHER INFORMATION

The vaccine contains inactivated bluetongue virus serotypes 2 and 4 with aluminium hydroxide and saponin adjuvants. It induces an active and specific immunity against bluetongue virus serotypes 2 and 4 in the vaccinated animals.

Not all pack sizes may be marketed.

Pack sizes:
Box of 1 bottle of 10 doses (1 x 10 ml)
Box of 1 bottle of 50 doses (1 x 50 ml)
Box of 10 bottles of 50 doses (10 x 50 ml)
Box of 1 bottle of 100 doses (1 x 100 ml)
Box of 10 bottles of 100 doses (10 x 100 ml)

The manufacture, import, possession, sale, supply and/or use of BTVPUR AlSap 2-4 may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation. Any person intending to manufacture, import, possess, sell, supply and use BTVPUR AlSap 2-4 must consult the relevant Member State's competent authority on the current vaccination policies prior to the manufacture, import, possession, sale, supply and/or use.